3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
4
Genitourinary
3
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Endocrine
2
CNS
2
Breast
2
Thoracic
1
NET
1
Lymphoid
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
2
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
pembrolizumab
11
Cyclophosphamide
8
Gemcitabine
7
Cisplatin
7
tislelizumab
5
Docetaxel
5
Nivolumab
4
Injections
4
spartalizumab
3
regorafenib
3
Trastuzumab
3
Oncolytic Virotherapy
3
Irinotecan
3
Filgrastim
3
Drug Therapy
3
Doxorubicin
3
Carboplatin
3
Bortezomib
3
tazemetostat
2
pazopanib
2
liposomal doxorubicin
2
ganitumab
2
conatumumab
2
belinostat
2
Temozolomide
2
Taxes
2
Tamoxifen
2
Sorafenib
2
Riluzole
2
Radiotherapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
entrectinib
×
Thoracic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA